Overview

* Theratechnologies ( THTX ) Q2 revenue of $17.7 mln beats analyst expectations, per LSEG data

* Net loss for Q2 was $4.46 mln, missing analyst estimates, per LSEG data

* Co entered definitive agreement to be acquired by Future Pak affiliate

Outlook

* Theratechnologies ( THTX ) withdraws Fiscal 2025 revenue and EBITDA guidance, due to Future Pak deal

* Company plans to launch EGRIFTA WR, improved version of medication for HIV in Q3 2025.

* Theratechnologies ( THTX ) sees strong demand for EGRIFTA SV and Trogarzo.

* Company anticipates growth contingent on reimbursement and supply chain.

Result Drivers

* SUPPLY DISRUPTION - EGRIFTA SV sales declined due to supply disruption, impacting revenue negatively

* STRONG DEMAND - Record high patient enrollments for EGRIFTA SV indicate strong demand, per CEO Paul Lévesque

* TROGARZO SALES - Increased Trogarzo sales driven by higher unit sales and selling prices

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $17.70 $17.50

Revenue mln mln (2

Analysts

)

Q2 Net Miss -$4.46 -$866,00

Income mln 0 (2

Analysts

)

Q2 Beat $906,000 -$172,00

Adjusted 0 (1

EBITDA Analyst)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Theratechnologies Inc ( THTX ) is C$5.53, about 22.2% above its July 8 closing price of C$4.30

* The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)